Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors

Gabor L. Toller, Judit E. Horvath, Andrew V Schally, Gabor Halmos, Jozsef L. Varga, Kate Groot, David Chism, Marta Zarandi

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of various human cancers by multiple mechanisms, which include direct effects on tumor cells through the splice variants (SV) of the GHRH receptor. Our findings suggest that the tumoral protein encoded by SV 1 (SV1) is a likely functional receptor. The aim of this study was to develop a polyclonal antiserum against a polypeptide analog of segment 1-25 of the putative SV1 receptor protein. Rabbits were immunized with [Ala-23]SV1 (1-25)-Tyr-26-Cys-27-NH2 as a hapten, conjugated to BSA or keyhole limpet hemocyanin. The antisera thus generated were evaluated by RIA for binding to the radiolabeled hapten. The specificity and sensitivity of the antisera were studied on xenografts of RL and HT human non-Hodgkin's lymphomas. The sera raised against keyhole limpet hemocyanin-SV1 hapten, showed binding values of 50-75% at a 1:56,000 dilution. In Western blot analyses, the purified polyclonal antibody recognized a specific signal with a molecular mass of ≈40 kDa in RL and HT lymphomas. This band corresponds to the estimated molecular mass of the GHRH receptor isoform encoded by SV1. RT-PCR and ligand binding studies also revealed the expression of SV1 and the presence of high-affinity binding sites for GHRH on RL and HT tumors. Because the antiserum developed recognizes the tumoral GHRH receptor protein encoded by SV1, it should be of value in various investigations.

Original languageEnglish
Pages (from-to)15160-15165
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume101
Issue number42
DOIs
StatePublished - Oct 19 2004
Externally publishedYes

Fingerprint

Haptens
Immune Sera
Protein Isoforms
Growth Hormone-Releasing Hormone
Neoplasms
Heterografts
Non-Hodgkin's Lymphoma
Lymphoma
Proteins
Western Blotting
Binding Sites
Rabbits
Ligands
Sensitivity and Specificity
Polymerase Chain Reaction
Peptides
somatotropin releasing hormone receptor
Antibodies
Growth
Serum

Keywords

  • Growth hormone-releasing hormone receptor
  • Non-Hodgkin's lymphoma
  • Polyclonal antibody
  • Splice variant

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors. / Toller, Gabor L.; Horvath, Judit E.; Schally, Andrew V; Halmos, Gabor; Varga, Jozsef L.; Groot, Kate; Chism, David; Zarandi, Marta.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, No. 42, 19.10.2004, p. 15160-15165.

Research output: Contribution to journalArticle

Toller, Gabor L. ; Horvath, Judit E. ; Schally, Andrew V ; Halmos, Gabor ; Varga, Jozsef L. ; Groot, Kate ; Chism, David ; Zarandi, Marta. / Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors. In: Proceedings of the National Academy of Sciences of the United States of America. 2004 ; Vol. 101, No. 42. pp. 15160-15165.
@article{3303e76f8bac40a8b4ef4afae455b225,
title = "Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors",
abstract = "Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of various human cancers by multiple mechanisms, which include direct effects on tumor cells through the splice variants (SV) of the GHRH receptor. Our findings suggest that the tumoral protein encoded by SV 1 (SV1) is a likely functional receptor. The aim of this study was to develop a polyclonal antiserum against a polypeptide analog of segment 1-25 of the putative SV1 receptor protein. Rabbits were immunized with [Ala-23]SV1 (1-25)-Tyr-26-Cys-27-NH2 as a hapten, conjugated to BSA or keyhole limpet hemocyanin. The antisera thus generated were evaluated by RIA for binding to the radiolabeled hapten. The specificity and sensitivity of the antisera were studied on xenografts of RL and HT human non-Hodgkin's lymphomas. The sera raised against keyhole limpet hemocyanin-SV1 hapten, showed binding values of 50-75{\%} at a 1:56,000 dilution. In Western blot analyses, the purified polyclonal antibody recognized a specific signal with a molecular mass of ≈40 kDa in RL and HT lymphomas. This band corresponds to the estimated molecular mass of the GHRH receptor isoform encoded by SV1. RT-PCR and ligand binding studies also revealed the expression of SV1 and the presence of high-affinity binding sites for GHRH on RL and HT tumors. Because the antiserum developed recognizes the tumoral GHRH receptor protein encoded by SV1, it should be of value in various investigations.",
keywords = "Growth hormone-releasing hormone receptor, Non-Hodgkin's lymphoma, Polyclonal antibody, Splice variant",
author = "Toller, {Gabor L.} and Horvath, {Judit E.} and Schally, {Andrew V} and Gabor Halmos and Varga, {Jozsef L.} and Kate Groot and David Chism and Marta Zarandi",
year = "2004",
month = "10",
day = "19",
doi = "10.1073/pnas.0406348101",
language = "English",
volume = "101",
pages = "15160--15165",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "42",

}

TY - JOUR

T1 - Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors

AU - Toller, Gabor L.

AU - Horvath, Judit E.

AU - Schally, Andrew V

AU - Halmos, Gabor

AU - Varga, Jozsef L.

AU - Groot, Kate

AU - Chism, David

AU - Zarandi, Marta

PY - 2004/10/19

Y1 - 2004/10/19

N2 - Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of various human cancers by multiple mechanisms, which include direct effects on tumor cells through the splice variants (SV) of the GHRH receptor. Our findings suggest that the tumoral protein encoded by SV 1 (SV1) is a likely functional receptor. The aim of this study was to develop a polyclonal antiserum against a polypeptide analog of segment 1-25 of the putative SV1 receptor protein. Rabbits were immunized with [Ala-23]SV1 (1-25)-Tyr-26-Cys-27-NH2 as a hapten, conjugated to BSA or keyhole limpet hemocyanin. The antisera thus generated were evaluated by RIA for binding to the radiolabeled hapten. The specificity and sensitivity of the antisera were studied on xenografts of RL and HT human non-Hodgkin's lymphomas. The sera raised against keyhole limpet hemocyanin-SV1 hapten, showed binding values of 50-75% at a 1:56,000 dilution. In Western blot analyses, the purified polyclonal antibody recognized a specific signal with a molecular mass of ≈40 kDa in RL and HT lymphomas. This band corresponds to the estimated molecular mass of the GHRH receptor isoform encoded by SV1. RT-PCR and ligand binding studies also revealed the expression of SV1 and the presence of high-affinity binding sites for GHRH on RL and HT tumors. Because the antiserum developed recognizes the tumoral GHRH receptor protein encoded by SV1, it should be of value in various investigations.

AB - Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of various human cancers by multiple mechanisms, which include direct effects on tumor cells through the splice variants (SV) of the GHRH receptor. Our findings suggest that the tumoral protein encoded by SV 1 (SV1) is a likely functional receptor. The aim of this study was to develop a polyclonal antiserum against a polypeptide analog of segment 1-25 of the putative SV1 receptor protein. Rabbits were immunized with [Ala-23]SV1 (1-25)-Tyr-26-Cys-27-NH2 as a hapten, conjugated to BSA or keyhole limpet hemocyanin. The antisera thus generated were evaluated by RIA for binding to the radiolabeled hapten. The specificity and sensitivity of the antisera were studied on xenografts of RL and HT human non-Hodgkin's lymphomas. The sera raised against keyhole limpet hemocyanin-SV1 hapten, showed binding values of 50-75% at a 1:56,000 dilution. In Western blot analyses, the purified polyclonal antibody recognized a specific signal with a molecular mass of ≈40 kDa in RL and HT lymphomas. This band corresponds to the estimated molecular mass of the GHRH receptor isoform encoded by SV1. RT-PCR and ligand binding studies also revealed the expression of SV1 and the presence of high-affinity binding sites for GHRH on RL and HT tumors. Because the antiserum developed recognizes the tumoral GHRH receptor protein encoded by SV1, it should be of value in various investigations.

KW - Growth hormone-releasing hormone receptor

KW - Non-Hodgkin's lymphoma

KW - Polyclonal antibody

KW - Splice variant

UR - http://www.scopus.com/inward/record.url?scp=6344238528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6344238528&partnerID=8YFLogxK

U2 - 10.1073/pnas.0406348101

DO - 10.1073/pnas.0406348101

M3 - Article

VL - 101

SP - 15160

EP - 15165

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 42

ER -